LyphoMed Inc form division call IPHARM develop full line generic proprietary ophthalmic pharmaceuticals. Lyphomed initial phase division produce product exclusively 200 mln dlr hospital market. The company phase IPHARM extend market include hospital non-hospital customer estimate value 800 mln dlrs 1 billion dlrs total. Ultimately Lyphomed IPHARM concentrate develop proprietary ophthalmic dosage forms. Lyphomed division already submit Abbreviated New Drug Applications Food Drug Administration submit six months. Lyphomed division operate Melrose Park manufacturing facility head Ramesh Acharya Lyphomed vice president manager. Reuter 